down arrow

Cidara Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US1717571079
USD
220.50
0.61 (0.28%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

219.86220.69

52 Week

15.22221.20
Valuation
Technical
Day's Volume

CASH

453.55 k

Shareholding (Mar 2025)

FII

1.55%

Held by 20 FIIs

DII

59.93%

Held by 8 DIIs

Promoter

32.02%

How big is Cidara Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Cidara Therapeutics, Inc. has a market capitalization of 286.63 million and reported net sales of 0.30 million with a net profit of -185.60 million over the latest four quarters.

As of Jun 18, Cidara Therapeutics, Inc. has a market capitalization of 286.63 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 0.30 million, while the sum of net profit for the same period is -185.60 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 163.31 million, and total assets amount to 215.58 million.

Read More

What does Cidara Therapeutics, Inc. do?

22-Jun-2025

Cidara Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing new anti-infectives, with a market cap of approximately $286.63 million and a recent net profit of -$23 million. The company has no dividend yield and is currently loss-making.

Overview: <BR>Cidara Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing new anti-infectives within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -23 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 286.63 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.22 <BR>Return on Equity: -71.08% <BR>Price to Book: 2.02<BR><BR>Contact Details: <BR>Address: 6310 Nancy Ridge Dr Ste 101, SAN DIEGO CA: 92121-3209 <BR>Tel: ['1 858 7526170', '1 858 3565932'] <BR>Fax: 1 302 6555049 <BR>Website: http://www.cidara.com/

Read More

Who are in the management team of Cidara Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Cidara Therapeutics, Inc. includes Mr. Daniel Burgess (Independent Chairman), Dr. Jeffrey Stein (President and CEO), and several Independent Directors: Dr. Timothy Franson, Dr. David Gollaher, Ms. Chrysa Mineo, and Mr. Theodore Schroeder. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Cidara Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Daniel Burgess, who serves as the Independent Chairman of the Board.<BR>- Dr. Jeffrey Stein, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Timothy Franson, who is an Independent Director.<BR>- Dr. David Gollaher, who is also an Independent Director.<BR>- Ms. Chrysa Mineo, who serves as an Independent Director.<BR>- Mr. Theodore Schroeder, who is another Independent Director. <BR><BR>This team is responsible for guiding the strategic direction and oversight of the company.

Read More

Is Cidara Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of October 5, 2023, Cidara Therapeutics, Inc. is considered attractive and undervalued, with a price-to-earnings ratio of 15.2 and a price-to-book ratio of 1.8, significantly lower than peers like Myriad Genetics and Amgen, while its stock performance has outpaced the Sensex, indicating potential market undervaluation.

As of 5 October 2023, Cidara Therapeutics, Inc. moved from fair to attractive. The company is currently undervalued. Key ratios include a price-to-earnings ratio of 15.2, a price-to-book ratio of 1.8, and a debt-to-equity ratio of 0.4. When compared to peers, Myriad Genetics, Inc. has a price-to-earnings ratio of 20.5, and Amgen Inc. shows a price-to-book ratio of 4.0, indicating that Cidara is trading at a discount relative to its industry counterparts.<BR><BR>Additionally, Cidara's recent stock performance has outpaced the Sensex, reinforcing the valuation story and suggesting that the market may not fully recognize its potential.

Read More

Is Cidara Therapeutics, Inc. technically bullish or bearish?

28-Oct-2025

As of October 24, 2025, Cidara Therapeutics, Inc. shows a mildly bullish trend with strong performance, highlighted by a year-to-date return of 246.43%, despite some bearish signals from the RSI.

As of 24 October 2025, the technical trend for Cidara Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is also bullish, indicating positive momentum. However, the monthly RSI is bearish, suggesting some weakness in price strength. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, and moving averages indicate a bullish stance on the daily chart. Dow Theory and OBV both show a mildly bullish trend on weekly and monthly bases.<BR><BR>In terms of performance, the stock has significantly outperformed the S&P 500 over multiple periods, with a year-to-date return of 246.43% compared to the S&P 500's 15.47%, and an impressive one-year return of 734.41% versus 16.90% for the index. Overall, the current technical stance is mildly bullish, driven primarily by the bullish MACD and moving averages, despite some bearish signals from the RSI and KST.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,576 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.03

stock-summary
Return on Equity

-23.37%

stock-summary
Price to Book

3.14

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-26 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
247.63%
0%
247.63%
6 Months
846.35%
0%
846.35%
1 Year
1145.06%
0%
1145.06%
2 Years
1311.83%
0%
1311.83%
3 Years
36705.21%
0%
36705.21%
4 Years
625.33%
0%
625.33%
5 Years
415.19%
0%
415.19%

Cidara Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Cidara Therapeutics, Inc. technically bullish or bearish?

As of 24 October 2025, the technical trend for Cidara Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is also bullish, indicating positive momentum. However, the monthly RSI is bearish, suggesting some weakness in price strength. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, and moving averages indicate a bullish stance on the daily chart. Dow Theory and OBV both show a mildly bullish trend on weekly and monthly bases. In terms of performance, the stock has significantly outperformed the S&P 500 over multiple periods, with a year-to-date return of 246.43% compared to the S&P 500's 15.47%, and an impressive one-year return of 734.41% versus 16.90% for the index. Overall, the current technical stance is mildly bullish, driven primarily by the bullish MACD and moving averages, despite some bearish signals f...

Read More

Is Cidara Therapeutics, Inc. technically bullish or bearish?

As of 24 October 2025, the technical trend for Cidara Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on both weekly and monthly time frames, and daily moving averages indicating bullish momentum. However, the monthly RSI is bearish, suggesting some weakness. The Bollinger Bands, KST, and Dow Theory are all indicating mildly bullish signals on both weekly and monthly time frames. In terms of performance, Cidara has significantly outperformed the S&P 500 over the past year, with a return of 734.41% compared to the S&P 500's 16.90%. However, it has underperformed in the last week, with a return of -8.27% against the S&P 500's 1.92%....

Read More

Is Cidara Therapeutics, Inc. technically bullish or bearish?

As of 24 October 2025, the technical trend for Cidara Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by a bullish MACD on both weekly and monthly time frames, and bullish moving averages on the daily chart. However, the monthly RSI is bearish, indicating some weakness. The stock has shown strong performance with a year-to-date return of 246.43%, significantly outperforming the S&P 500's 15.47% over the same period....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-200.99%
EBIT to Interest (avg)
-56.14
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.22
Sales to Capital Employed (avg)
0.32
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
93.57%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.31
EV to EBIT
-1.36
EV to EBITDA
-1.36
EV to Capital Employed
-4.91
EV to Sales
154.05
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-71.08%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 8 Schemes (6.5%)

Foreign Institutions

Held by 20 Foreign Institutions (1.55%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -9.36% vs 55.15% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-31.30",
          "val2": "-30.70",
          "chgp": "-1.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-25.70",
          "val2": "-23.50",
          "chgp": "-9.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -94.42% vs -63.82% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -578.49% vs 25.30% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.30",
          "val2": "23.30",
          "chgp": "-94.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-91.00",
          "val2": "-26.90",
          "chgp": "-238.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-84.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-170.30",
          "val2": "-25.10",
          "chgp": "-578.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-71,544.30%",
          "val2": "-1,162.20%",
          "chgp": "-7,038.21%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-31.30
-30.70
-1.95%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-25.70
-23.50
-9.36%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -9.36% vs 55.15% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
1.30
23.30
-94.42%
Operating Profit (PBDIT) excl Other Income
-91.00
-26.90
-238.29%
Interest
0.00
0.00
Exceptional Items
-84.90
0.00
Consolidate Net Profit
-170.30
-25.10
-578.49%
Operating Profit Margin (Excl OI)
-71,544.30%
-1,162.20%
-7,038.21%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -94.42% vs -63.82% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -578.49% vs 25.30% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Cidara Therapeutics, Inc. stock-summary
stock-summary
Cidara Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Cidara Therapeutics Inc., is a clinical-stage biotechnology company focused on developing new anti-infectives. The Company’s lead product candidate is rezafungin acetate, which is a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. The Company is also leveraging its novel Cloudbreak platform to develop antibody-drug conjugates for the treatment of serious viral and Gram-negative bacterial infections. Cloudbreak is the immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens.
Company Coordinates stock-summary
Company Details
6310 Nancy Ridge Dr Ste 101 , SAN DIEGO CA : 92121-3209
stock-summary
Tel: 1 858 75261701 858 3565932
stock-summary
http://www.cidara.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."